Search results
Showing 31 to 45 of 109 results for melanoma
Evidence-based recommendations on photodynamic therapy for non-melanoma skin tumours (including premalignant and primary non-metastatic skin lesions). This involves applying (or sometimes injecting) a photosensitising agent and using light to activate it, destroying the tumour cells.
View recommendations for HTG99Show all sections
NICE has developed a medtech innovation briefing (MIB) on digital technologies for the detection of melanoma .
In development Reference number: GID-IPG10448 Expected publication date: 15 October 2026
AMBLor for identifying low-risk non-ulcerated early-stage cutaneous melanomas (MIB294)
NICE has developed a medtech innovation briefing (MIB) on AMBLor for identifying low-risk non-ulcerated early-stage cutaneous melanomas .
VivaScope 1500 and 3000 imaging systems for detecting skin cancer lesions (HTG388)
Evidence-based recommendations on the VivaScope 1500 and 3000 imaging systems for detecting skin cancer lesions.
This guideline covers how to communicate the risks and benefits of natural sunlight exposure (specifically, the ultraviolet rays UVA and UVB) to help people understand why they may need to modify their behaviour to reduce their risk of skin cancer and vitamin D deficiency.
Improving outcomes for people with skin tumours including melanoma (CSG8)
This guideline covers how healthcare services for people with skin cancers should be organised. It aims to improve diagnosis and care by recommending which healthcare professionals should be involved and at which stage.
Evidence-based recommendations on melphalan chemosaturation with percutaneous hepatic artery perfusion and hepatic vein isolation for primary or metastatic cancer in the liver. This involves diverting the blood flow from the liver to the rest of the body while the drug is delivered directly into the liver.
View recommendations for HTG575Show all sections
Find out what guidance is being considered for development
This guideline covers identifying children, young people and adults with symptoms that could be caused by cancer. It outlines appropriate investigations in primary care, and selection of people to refer for a specialist opinion. It aims to help people understand what to expect if they have symptoms that may suggest cancer.
Show all sections
Sections for NG12
Histological margins: What is the optimal histological excision margin in stage 0 melanoma?
Histological margins: What is the optimal histological excision margin in stage 0 melanoma? Any explanatory notes(if applicable) For a...
effectiveness of localised treatment for people with stages III and IV melanoma? Any explanatory notes(if applicable) For a short...
be used for risk stratification and treatment planning for people with melanoma? Any explanatory notes(if applicable) For a short...
effect of drug therapy for concurrent conditions on melanoma survival: In people diagnosed with melanoma what is the effect...
Metastatic malignant disease of unknown primary origin in adults: diagnosis and management (CG104)
This guideline covers diagnosing and managing secondary cancer in people aged 18 and over when the site of the primary cancer is unknown. This includes people who have had treatment for cancer before. It aims to improve quality of life by offering advice on tests for identifying the site of the primary cancer and options for managing the person’s condition.